Quantitative body fluid proteomics in medicine — A focus on minimal invasiveness

Journal of Proteomics

Volumn 153, Issue , 2017, Pages 30-43

  Csősz, Éva ^a   Kalló, Gergő ^a   Márkus, Bernadett ^a   Deák, Eszter ^a   Csutak, Adrienne ^a   Tőzsér, József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

AMP; Biomarker; Body fluid; Quantitative proteomics; Targeted proteomics

Indexed keywords

BIOLOGICAL MARKER; SALIVA PROTEIN;

BODY FLUID; EXOSOME; EYE DISEASE; GYNECOLOGY; HUMAN; INNATE IMMUNITY; LACRIMAL FLUID; NOSE SECRETION; OBSTETRICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SALIVA; SWEAT; SYSTEMIC DISEASE; URINE; UROGENITAL TRACT DISEASE; VAGINA DISCHARGE; ANIMAL; CHEMISTRY; PROCEDURES; WORKFLOW;

ANIMALS; BIOMARKERS; BODY FLUIDS; HUMANS; PROTEOMICS; WORKFLOW;

EID: 84994759702     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2016.08.009     Document Type: Review

References (215)

1. Picotti, P., Aebersold, R., Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 9 (2012), 555–566, 10.1038/nmeth.2015.
2. Rabilloud, T., Lelong, C., Two-dimensional gel electrophoresis in proteomics: a tutorial. J. Proteomics 74 (2011), 1829–1841, 10.1016/j.jprot.2011.05.040.
3. Nolan, J.P., Mandy, F., Multiplexed and microparticle-based analyses: quantitative tools for the large-scale analysis of biological systems. Cytometry. Part A: The Journal of the International Society for Analytical Cytology 69 (2006), 318–325, 10.1002/cyto.a.20266.
4. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 2008, 222, 10.1038/msb.2008.61.
5. M. Ramström, C. Hagman, J.K. Mitchell, P.J. Derrick, P. Håkansson, J. Bergquist, Depletion of high-abundant proteins in body fluids prior to liquid chromatography fourier transform ion cyclotron resonance mass spectrometry., J. Proteome Res. 4 410–6. doi: http://dx.doi.org/10.1021/pr049812a.
6. Caragata, M., Shah, A.K., Schulz, B.L., Hill, M.M., Punyadeera, C., Enrichment and identification of glycoproteins in human saliva using lectin magnetic bead arrays. Anal. Biochem. 497 (2016), 76–82, 10.1016/j.ab.2015.11.024.
7. Grønborg, M., Kristiansen, T.Z., Stensballe, A., Andersen, J.S., Ohara, O., Mann, M., et al. A mass spectrometry-based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate. Molecular & Cellular Proteomics: MCP. 1 (2002), 517–527.
8. Whiteaker, J.R., Paulovich, A.G., Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification. Clin. Lab. Med. 31 (2011), 385–396, 10.1016/j.cll.2011.07.004.
9. Anderson, N.L., Anderson, N.G., Haines, L.R., Hardie, D.B., Olafson, R.W., Pearson, T.W., Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 3 (2004), 235–244.
10. Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H.H., Hegi, T., Nitsch, R.M., et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide. Arch. Neurol. 60 (2003), 1202–1206, 10.1001/archneur.60.9.1202.
11. Churcher, I., Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 6 (2006), 579–595.
12. Hu, Y.-Y., He, S.-S., Wang, X.-C., Duan, Q.-H., Khatoon, S., Iqbal, K., et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 320 (2002), 156–160.
13. Group, B.D.W., Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69 (2001), 89–95, 10.1067/mcp.2001.113989.
14. Rodriguez, H., Rivers, R., Kinsinger, C., Mesri, M., Hiltke, T., Rahbar, A., et al. Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective. Proteomics Clin. Appl. 4 (2010), 904–914, 10.1002/prca.201000057.
15. Ludwig, J.A., Weinstein, J.N., Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5 (2005), 845–856, 10.1038/nrc1739.
16. Anderson, N.L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 56 (2010), 177–185, 10.1373/clinchem.2009.126706.
17. Kulasingam, V., Diamandis, E.P., Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5 (2008), 588–599, 10.1038/ncponc1187.
18. Füzéry, A.K., Levin, J., Chan, M.M., Chan, D.W., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clinical Proteomics, 10, 2013, 13, 10.1186/1559-0275-10-13.
19. Zhang, Z., Chan, D.W., The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 19 (2010), 2995–2999, 10.1158/1055-9965.EPI-10-0580.
20. Zhang, Z., Bast, R.C., Yu, Y., Li, J., Sokoll, L.J., Rai, A.J., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64 (2004), 5882–5890, 10.1158/0008-5472.CAN-04-0746.
21. Rai, A.J., Zhang, Z., Rosenzweig, J., Shih, I.-M., Pham, T., Fung, E.T., et al. Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab. Med. 126 (2002), 1518–1526, 10.1043/0003-9985(2002)126<1518:PATTMD>2.0.CO;2.
22. Oberg, A.L., Vitek, O., Statistical design of quantitative mass spectrometry-based proteomic experiments. J. Proteome Res. 8 (2009), 2144–2156, 10.1021/pr8010099.
23. Shultz, E.K., Multivariate receiver-operating characteristic curve analysis: prostate cancer screening as an example. Clin. Chem. 41 (1995), 1248–1255.
24. Z.-Z. Li, X.-Z. Lu, J.-B. Liu, L. Chen, Serum retinol-binding protein 4 levels in patients with diabetic retinopathy., J. Int. Med. Res. 38. 95–9.
25. Csősz, É., Boross, P., Csutak, A., Berta, A., Tóth, F., Póliska, S., et al. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J. Proteomics 75 (2012), 2196–2204, 10.1016/j.jprot.2012.01.019.
26. Prabha, J.L., Tear Secretion-A Short Review 6 (2014), 155–157.
27. Fullard, R.J., Snyder, C., Protein levels in nonstimulated and stimulated tears of normal human subjects. Invest. Ophthalmol. Vis. Sci. 31 (1990), 1119–1126.
28. Tiffany, J.M., Tears in health and disease. Eye (Lond.) 17 (2003), 923–926, 10.1038/sj.eye.6700566.
29. Contents, S., Contents, F., An, P.I., Immunity, I., The front line of host defense. Search, 2009, 1–9.
30. de Souza, G.A., Godoy, L.M.F., Mann, M., Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol., 7, 2006, R72, 10.1186/gb-2006-7-8-R72.
31. Zhou, L., Zhao, S.Z., Koh, S.K., Chen, L., Vaz, C., Tanavde, V., et al. In-depth analysis of the human tear proteome. J. Proteomics 75 (2012), 3877–3885, 10.1016/j.jprot.2012.04.053.
32. Li, N., Wang, N., Zheng, J., Liu, X.M., Lever, O.W., Erickson, P.M., et al. Characterization of human tear proteome using multiple proteomic analysis techniques. J. Proteome Res. 4 (2005), 2052–2061, 10.1021/pr0501970.
33. Janssen, P.T., van Bijsterveld, O.P., Origin and biosynthesis of human tear fluid proteins. Invest. Ophthalmol. Vis. Sci. 24 (1983), 623–630.
34. Walcott, B., The lacrimal gland and its veil of tears. News Physiol. Sci. 13 (1998), 97–103.
35. Zhou, L., Beuerman, R.W., Tear analysis in ocular surface diseases. Prog. Retin. Eye Res. 31 (2012), 527–550, 10.1016/j.preteyeres.2012.06.002.
36. von Thun und Hohenstein-Blaul, N., Funke, S., Grus, F.H., Tears as a source of biomarkers for ocular and systemic diseases. Exp. Eye Res. 117 (2013), 126–137, 10.1016/j.exer.2013.07.015.
37. Willcox, M.D.P., Zhao, Z., Naduvilath, T., Lazon de la Jara, P., Cytokine changes in tears and relationship to contact lens discomfort. Mol. Vis. 21 (2015), 293–305.
38. Zhou, L., Beuerman, R.W., Chan, C.M., Zhao, S.Z., Li, X.R., Yang, H., et al. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J. Proteome Res. 8 (2009), 4889–4905, 10.1021/pr900686s.
39. Srinivasan, S., Thangavelu, M., Zhang, L., Green, K.B., Nichols, K.K., iTRAQ quantitative proteomics in the analysis of tears in dry eye patients. Invest. Ophthalmol. Vis. Sci. 53 (2012), 5052–5059, 10.1167/iovs.11-9022.
40. Aluru, S.V., Agarwal, S., Srinivasan, B., Iyer, G.K., Rajappa, S.M., Tatu, U., et al. Lacrimal proline rich 4 (LPRR4) protein in the tear fluid is a potential biomarker of dry eye syndrome. PLoS One, 7, 2012, e51979, 10.1371/journal.pone.0051979.
41. Grus, F.H., Podust, V.N., Bruns, K., Lackner, K., Fu, S., Dalmasso, E.A., et al. SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye. Invest. Ophthalmol. Vis. Sci. 46 (2005), 863–876, 10.1167/iovs.04-0448.
42. Koo, B.-S., Lee, D.-Y., Ha, H.-S., Kim, J.-C., Kim, C.-W., Comparative analysis of the tear protein expression in blepharitis patients using two-dimensional electrophoresis. J. Proteome Res. 4 (2005), 719–724, 10.1021/pr0498133.
43. Lei, Z., Beuerman, R.W., Chew, A.P., Koh, S.K., Cafaro, T.A., Urrets-Zavalia, E.A., et al. Quantitative analysis of N-linked glycoproteins in tear fluid of climatic droplet keratopathy by glycopeptide capture and iTRAQ. J. Proteome Res. 8 (2009), 1992–2003, 10.1021/pr800962q.
44. Acera, A., Vecino, E., Rodríguez-Agirretxe, I., Aloria, K., Arizmendi, J.M., Morales, C., et al. Changes in tear protein profile in keratoconus disease. Eye (Lond.) 25 (2011), 1225–1233, 10.1038/eye.2011.105.
45. Balasubramanian, S.A., Wasinger, V.C., Pye, D.C., Willcox, M.D.P., Preliminary identification of differentially expressed tear proteins in keratoconus. Mol. Vis. 19 (2013), 2124–2134.
46. Ananthi, S., Chitra, T., Bini, R., Prajna, N.V., Lalitha, P., Dharmalingam, K., Comparative analysis of the tear protein profile in mycotic keratitis patients. Mol. Vis. 14 (2008), 500–507.
47. Leonardi, A., Palmigiano, A., Mazzola, E.A., Messina, A., Milazzo, E.M.S., Bortolotti, M., et al. Identification of human tear fluid biomarkers in vernal keratoconjunctivitis using iTRAQ quantitative proteomics. Allergy 69 (2014), 254–260, 10.1111/all.12331.
48. Salvisberg, C., Tajouri, N., Hainard, A., Burkhard, P.R., Lalive, P.H., Turck, N., Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. Proteomics Clin. Appl. 8 (2014), 185–194, 10.1002/prca.201300053.
49. Kalló, G., Emri, M., Varga, Z., Ujhelyi, B., Tőzsér, J., Csutak, A., et al. Changes in the chemical barrier composition of tears in Alzheimer's disease reveal potential tear diagnostic biomarkers. PLoS One, 1–14, 2016, 10.1371/journal.pone.0158000.
50. Tomosugi, N., Kitagawa, K., Takahashi, N., Sugai, S., Ishikawa, I., Diagnostic potential of tear proteomic patterns in Sjögren's syndrome. J. Proteome Res. 4 (2005), 820–825, 10.1021/pr0497576.
51. Lebrecht, A., Boehm, D., Schmidt, M., Koelbl, H., Grus, F.H., Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry to detect breast cancer markers in tears and serum. Cancer Genomics Proteomics 6 (2009), 75–84 doi:6/2/75 [pii].
52. A. Lebrecht, D. Boehm, M. Schmidt, H. Koelbl, R.L. Schwirz, F.H. Grus, Diagnosis of breast cancer by tear proteomic pattern., Cancer Genomics Proteomics. 6 177–82.
53. Li, S., Sack, R., Vijmasi, T., Sathe, S., Beaton, A., Quigley, D., et al. Antibody protein array analysis of the tear film cytokines. Optom. Vis. Sci. 85 (2008), 653–660, 10.1097/OPX.0b013e3181824e20.
54. Wei, Y., Gadaria-Rathod, N., Epstein, S., Asbell, P., Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Invest. Ophthalmol. Vis. Sci. 54 (2013), 8327–8336, 10.1167/iovs.13-12132.
55. Le Guezennec, X., Quah, J., Tong, L., Kim, N., Human tear analysis with miniaturized multiplex cytokine assay on “ wall-less ” 96-well plate. Mol. Vis. 21 (2015), 1151–1161.
56. Wong, T.T., Zhou, L., Li, J., Tong, L., Zhao, S.Z., Li, X.R., et al. Proteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glaucoma medication. Invest. Ophthalmol. Vis. Sci. 52 (2011), 7385–7391, 10.1167/iovs.10-6532.
57. Wakamatsu, T.H., Dogru, M., Tsubota, K., Tearful relations: oxidative stress, inflammation and eye diseases. Arq. Bras. Oftalmol. 71 (2008), 72–79, 10.1590/S0004-27492008000700015.
58. Çomoğlu, S.S., Güven, H., Acar, M., Öztürk, G., Koçer, B., Tear levels of tumor necrosis factor-alpha in patients with Parkinson's disease. Neurosci. Lett. 553 (2013), 63–67, 10.1016/j.neulet.2013.08.019.
59. Devos, D., Forzy, G., de Seze, J., Caillez, S., Louchart, P., Gallois, P., et al. Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. J. Neurol. 248 (2001), 672–675, 10.1007/PL00007833.
60. Humphrey, S.P., Williamson, R.T., A review of saliva: normal composition, flow, and function. J. Prosthet. Dent. 85 (2001), 162–169, 10.1067/mpr.2001.113778.
61. de Almeida, P.D.V., Grégio, A.M.T., Machado, M.A.N., de Lima, A.A.S., Azevedo, L.R., Saliva composition and functions: a comprehensive review. J. Contemp. Dent. Pract. 9 (2008), 72–80.
62. Schulz, B.L., Cooper-White, J., Punyadeera, C.K., Saliva proteome research: current status and future outlook. Crit. Rev. Biotechnol. 33 (2013), 246–259, 10.3109/07388551.2012.687361.
63. N. Ramasubbu, V. Paloth, Y. Luo, G.D. Brayer, M.J. Levine, Structure of human salivary alpha-amylase at 1.6 A resolution: implications for its role in the oral cavity., Acta Crystallogr. Sect. D: Biol. Crystallogr. 52 (1996) 435–46. doi: http://dx.doi.org/10.1107/S0907444995014119.
64. Hu, S., Xie, Y., Ramachandran, P., Ogorzalek Loo, R.R., Li, Y., Loo, J.A., et al. Large-scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and two-dimensional gel electrophoresis-mass spectrometry. Proteomics 5 (2005), 1714–1728, 10.1002/pmic.200401037.
65. Denny, P., Hagen, F.K., Hardt, M., Liao, L., Yan, W., Arellanno, M., et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J. Proteome Res. 7 (2008), 1994–2006, 10.1021/pr700764j.
66. Guo, T., Rudnick, P.A., Wang, W., Lee, C.S., Devoe, D.L., Balgley, B.M., Characterization of the human salivary proteome by capillary isoelectric focusing/nanoreversed-phase liquid chromatography coupled with ESI-tandem MS. J. Proteome Res. 5 (2006), 1469–1478, 10.1021/pr060065m.
67. Lin, L.Y., Chang, C.C., Determination of protein concentration in human saliva. Gaoxiong Yi Xue Ke Xue Za Zhi = The Kaohsiung Journal of Medical Sciences 5 (1989), 389–397.
68. Shaila, M., Pai, G.P., Shetty, P., Salivary protein concentration, flow rate, buffer capacity and pH estimation: a comparative study among young and elderly subjects, both normal and with gingivitis and periodontitis. Journal of Indian Society of Periodontology 17 (2013), 42–46, 10.4103/0972-124X.107473.
69. Henskens, Y.M., van der Velden, U., Veerman, E.C., Amerongen, A.V.N., Protein, albumin and cystatin concentrations in saliva of healthy subjects and of patients with gingivitis or periodontitis. J. Periodontal Res. 28 (1993), 43–48.
70. Ngounou Wetie, A.G., Wormwood, K.L., Charette, L., Ryan, J.P., Woods, A.G., Darie, C.C., Comparative two-dimensional polyacrylamide gel electrophoresis of the salivary proteome of children with autism spectrum disorder. J. Cell. Mol. Med. 19 (2015), 2664–2678, 10.1111/jcmm.12658.
71. Streckfus, C.F., Mayorga-Wark, O., Arreola, D., Edwards, C., Bigler, L., Dubinsky, W.P., Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest. 26 (2008), 159–167, 10.1080/07357900701783883.
72. Streckfus, C.F., Storthz, K.A., Bigler, L., Dubinsky, W.P., A comparison of the proteomic expression in pooled saliva specimens from individuals diagnosed with ductal carcinoma of the breast with and without lymph node involvement. Journal of Oncology, 2009, 2009, 737619, 10.1155/2009/737619.
73. de Jong, E.P., Xie, H., Onsongo, G., Stone, M.D., Chen, X.-B., Kooren, J.A., et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. PLoS One, 5, 2010, e11148, 10.1371/journal.pone.0011148.
74. Winck, F.V., Ribeiro, A.C.P., Domingues, R.R., Ling, L.Y., Riaño-Pachón, D.M., Rivera, C., et al. Insights into immune responses in oral cancer through proteomic analysis of saliva and salivary extracellular vesicles. Sci. Rep., 5, 2015, 16305, 10.1038/srep16305.
75. Wu, C.-C., Chu, H.-W., Hsu, C.-W., Chang, K.-P., Liu, H.-P., Saliva proteome profiling reveals potential salivary biomarkers for detection of oral cavity squamous cell carcinoma. Proteomics 15 (2015), 3394–3404, 10.1002/pmic.201500157.
76. Devic, I., Shi, M., Schubert, M.M., Lloid, M., Izutsu, K.T., Pan, C., et al. Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 20 (2014), 1048–1055, 10.1016/j.bbmt.2014.03.031.
77. Bassim, C.W., Ambatipudi, K.S., Mays, J.W., Edwards, D.A., Swatkoski, S., Fassil, H., et al. Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. J. Clin. Immunol. 32 (2012), 1390–1399, 10.1007/s10875-012-9738-4.
78. Ambatipudi, K.S., Swatkoski, S., Moresco, J.J., Tu, P.G., Coca, A., Anolik, J.H., et al. Quantitative proteomics of parotid saliva in primary Sjögren's syndrome. Proteomics 12 (2012), 3113–3120, 10.1002/pmic.201200208.
79. Thumbigere-Math, V., Michalowicz, B.S., de Jong, E.P., Griffin, T.J., Basi, D.L., Hughes, P.J., et al. Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 21 (2015), 46–56, 10.1111/odi.12204.
80. Flowers, S.A., Ali, L., Lane, C.S., Olin, M., Karlsson, N.G., Selected reaction monitoring to differentiate and relatively quantitate isomers of sulfated and unsulfated core 1 O-glycans from salivary MUC7 protein in rheumatoid arthritis. Mol. Cell. Proteomics 12 (2013), 921–931, 10.1074/mcp.M113.028878.
81. Giacomelli, C., Bazzichi, L., Giusti, L., Ciregia, F., Baldini, C., Da Valle, Y., et al. MALDI-TOF and SELDI-TOF analysis: “tandem” techniques to identify potential biomarker in fibromyalgia. Reumatismo 63 (2011), 165–170, 10.4081/reumatismo.2011.165.
82. Shintani, S., Hamakawa, H., Ueyama, Y., Hatori, M., Toyoshima, T., Identification of a truncated cystatin SA-I as a saliva biomarker for oral squamous cell carcinoma using the SELDI ProteinChip platform. Int. J. Oral Maxillofac. Surg. 39 (2010), 68–74, 10.1016/j.ijom.2009.10.001.
83. Gallo, C., Ciavarella, D., Santarelli, A., Ranieri, E., Colella, G., Lo Muzio, L., et al. Potential salivary proteomic markers of oral squamous cell carcinoma. Cancer Genomics Proteomics 13 (2016), 55–62.
84. Ryu, O.H., Atkinson, J.C., Hoehn, G.T., Illei, G.G., Hart, T.C., Identification of parotid salivary biomarkers in Sjögren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology 45 (2006), 1077–1086, 10.1093/rheumatology/kei212.
85. Bigler, L., Streckfus, C.F., Bigler, L.R., Zwick, M., The use of surface-enhanced laser desorption / ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: a feasibility study. J. Oral Pathol. Med. 125 (2006), 292–300, 10.1111/j.1600-0714.2006.00427.x.
86. Ardito, F., Giuliani, M., Perrone, D., Giannatempo, G., Di Fede, O., Favia, G., et al. Expression of salivary biomarkers in patients with Oral Mucositis: evaluation by SELDI-TOF/MS. Oral Dis., 2015, 10.1111/odi.12405 (n/a–n/a).
87. J.K. Chen, E. Eisenberg, D.J. Krutchkoff, R. V Katz, Changing trends in oral cancer in the United States, 1935 to 1985: a Connecticut study., J. Oral Maxillofac. Surg. 49 (1991) 1152–8.
88. Levi, F., La Vecchia, C., Randimbison, L., Te, V.C., Cancer incidence and mortality in young adults in Vaud, Switzerland, 1974–1992. Int. J. Cancer 61 (1995), 606–610.
89. Metz-Boutigue, M.-H., Shooshtarizadeh, P., Prevost, G., Haikel, Y., Chich, J.-F., Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. Curr. Pharm. Des. 16 (2010), 1024–1039.
90. Wiesner, J., Vilcinskas, A., Antimicrobial peptides: the ancient arm of the human immune system. Virulence 1 (2010), 440–464, 10.4161/viru.1.5.12983.
91. Csősz, É., Emri, G., Kalló, G., Tsaprailis, G., Tőzsér, J., Highly abundant defense proteins in human sweat as revealed by targeted proteomics and label-free quantification mass spectrometry. J. Eur. Acad. Dermatol. Venereol. 29 (2015), 2024–2031, 10.1111/jdv.13221.
92. Hassan, M.I., Waheed, A., Yadav, S., Singh, T.P., Ahmad, F., Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell. Mol. Life Sci. 66 (2009), 447–459, 10.1007/s00018-008-8463-x.
93. Rizzi, F., Bettuzzi, S., The clusterin paradigm in prostate and breast carcinogenesis. Endocr. Relat. Cancer 17 (2010), R1–17, 10.1677/ERC-09-0140.
94. Ganfornina, M.D., Do Carmo, S., Lora, J.M., Torres-Schumann, S., Vogel, M., Allhorn, M., et al. Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell 7 (2008), 506–515, 10.1111/j.1474-9726.2008.00395.x.
95. Gum, E.T., Swanson, R.A., Alano, C., Liu, J., Hong, S., Weinstein, P.R., et al. Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death. Stroke 35 (2004), 590–595, 10.1161/01.STR.0000110790.05859.DA.
96. Burian, M., Velic, A., Matic, K., Günther, S., Kraft, B., Gonser, L., et al. Quantitative proteomics of the human skin secretome reveal a reduction in immune defense mediators in ectodermal dysplasia patients. J. Investig. Dermatol. 135 (2015), 759–767, 10.1038/jid.2014.462.
97. Raiszadeh, M.M., Ross, M.M., Russo, P.S., Schaepper, M.A., Zhou, W., Deng, J., et al. Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins. J. Proteome Res. 11 (2012), 2127–2139, 10.1021/pr2007957.
98. Penneys, N.S., Haft, J., Rubin, R., Electrophoretic patterns of proteins in cystic fibrosis sweat. J. Investig. Dermatol. 83 (1984), 238–239.
99. Rieg, S., Steffen, H., Seeber, S., Humeny, A., Kalbacher, H., Dietz, K., et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J. Immunol. 174 (2005), 8003–8010, 10.1016/S0093-3619(08)70018-2.
100. Alexiou, D., Anagnostopoulos, A., Papadatos, C., Total free amino acids, ammonia, and protein in the sweat of children. Am. J. Clin. Nutr. 32 (1979), 750–752.
101. Patterson, M.J., Galloway, S.D., Nimmo, M.A., Variations in regional sweat composition in normal human males. Exp. Physiol. 85 (2000), 869–875.
102. Taylor, N.A., Machado-Moreira, C.A., Regional variations in transepidermal water loss, eccrine sweat gland density, sweat secretion rates and electrolyte composition in resting and exercising humans. Extreme Physiology & Medicine, 2, 2013, 4, 10.1186/2046-7648-2-4.
103. Sueno, K., Nakaima, N., Shingaki, K., Ura, M., Noda, Y., Kosugi, T., et al. Total protein concentration in selectively collected secretions from the middle and inferior meatus of the nose. Auris Nasus Larynx 13:Suppl 1 (1986), S85–S88.
104. Ruocco, L., Fattori, B., Romanelli, A., Martelloni, M., Casani, A., Samolewska, M., et al. A new collection method for the evaluation of nasal mucus proteins. Clin. Exp. Allergy 28 (1998), 881–888.
105. Cole, A.M., Dewan, P., Ganz, T., Innate antimicrobial activity of nasal secretions. Infect. Immun. 67 (1999), 3267–3275.
106. Meredith, S.D., Raphael, G.D., Baraniuk, J.N., Banks, S.M., Kaliner, M.A., The pathophysiology of rhinitis. III. The control of IgG secretion. J. Allergy Clin. Immunol. 84 (1989), 920–930.
107. Saieg, A., Brown, K.J., Pena, M.T., Rose, M.C., Preciado, D., Proteomic analysis of pediatric sinonasal secretions shows increased MUC5B mucin in CRS. Pediatr. Res. 77 (2015), 356–362, 10.1038/pr.2014.187.
108. Casado, B., Pannell, L.K., Viglio, S., Iadarola, P., Baraniuk, J.N., Analysis of the sinusitis nasal lavage fluid proteome using capillary liquid chromatography interfaced to electrospray ionization-quadrupole time of flight- tandem mass spectrometry. Electrophoresis 25 (2004), 1386–1393, 10.1002/elps.200305862.
109. Wang, H., Chavali, S., Mobini, R., Muraro, A., Barbon, F., Boldrin, D., et al. A pathway-based approach to find novel markers of local glucocorticoid treatment in intermittent allergic rhinitis. Allergy 66 (2011), 132–140, 10.1111/j.1398-9995.2010.02444.x.
110. Schiöth, H.B., Craft, S., Brooks, S.J., Frey, W.H., Benedict, C., Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol. Neurobiol. 46 (2012), 4–10, 10.1007/s12035-011-8229-6.
111. Liu, Z., Jiang, M., Kang, T., Miao, D., Gu, G., Song, Q., et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 34 (2013), 3870–3881, 10.1016/j.biomaterials.2013.02.003.
112. Hitti, J., Lapidus, J.A., Lu, X., Reddy, A.P., Jacob, T., Dasari, S., et al. Noninvasive diagnosis of intraamniotic infection: proteomic biomarkers in vaginal fluid. Am. J. Obstet. Gynecol., 203, 2010, 10.1016/j.ajog.2010.03.037 (32.e1–8).
113. Donders, G.G., Bosmans, E., Dekeersmaecker, A., Vereecken, A., Van Bulck, B., Spitz, B., Pathogenesis of abnormal vaginal bacterial flora. Am. J. Obstet. Gynecol. 182 (2000), 872–878.
114. Martin, H.L., Richardson, B.A., Nyange, P.M., Lavreys, L., Hillier, S.L., Chohan, B., et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J. Infect. Dis. 180 (1999), 1863–1868, 10.1086/315127.
115. Witkin, S.S., Linhares, I.M., Giraldo, P., Bacterial flora of the female genital tract: function and immune regulation. Best Pract. Res. Clin. Obstet. Gynaecol. 21 (2007), 347–354, 10.1016/j.bpobgyn.2006.12.004.
116. Zegels, G., Van Raemdonck, G.A., Tjalma, W.A., Van Ostade, X.W., Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci., 8, 2010, 63, 10.1186/1477-5956-8-63.
117. Shaw, J.L.V., Smith, C.R., Diamandis, E.P., Proteomic analysis of human cervico-vaginal fluid. J. Proteome Res. 6 (2007), 2859–2865, 10.1021/pr0701658.
118. Gravett, M.G., Thomas, A., Schneider, K.A., Reddy, A.P., Dasari, S., Jacob, T., et al. Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. J. Proteome Res. 6 (2007), 89–96, 10.1021/pr060149v.
119. Orfanelli, T., Jayaram, A., Doulaveris, G., Forney, L.J., Ledger, W.J., Witkin, S.S., Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal fluid: relation to vaginal components and bacterial composition. Reproductive Sciences (Thousand Oaks, Calif.) 21 (2014), 538–542, 10.1177/1933719113503416.
120. U. Rüetschi, A. Rosén, G. Karlsson, H. Zetterberg, L. Rymo, H. Hagberg, et al., Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation., J. Proteome Res. 4 2236–42. doi: http://dx.doi.org/10.1021/pr050139e.
121. Pereira, L., Reddy, A.P., Jacob, T., Thomas, A., Schneider, K.A., Dasari, S., et al. Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. J. Proteome Res. 6 (2007), 1269–1276, 10.1021/pr0605421.
122. Di Quinzio, M.K.W., Georgiou, H.M., Holdsworth-Carson, S.J., Ayhan, M., Heng, Y.J., Walker, S.P., et al. Proteomic analysis of human cervico-vaginal fluid displays differential protein expression in association with labor onset at term. J. Proteome Res. 7 (2008), 1916–1921, 10.1021/pr7006413.
123. Heng, Y.J., Di Quinzio, M.K.W., Permezel, M., Ayhan, M., Rice, G.E., Georgiou, H.M., Temporal proteomic analysis of human cervicovaginal fluid with impending term labor. J. Proteome Res. 9 (2010), 1344–1350, 10.1021/pr900892f.
124. Liong, S., Di Quinzio, M.K.W., Fleming, G., Permezel, M., Rice, G.E., Georgiou, H.M., Prediction of spontaneous preterm labour in at-risk pregnant women. Reproduction (Cambridge, England) 146 (2013), 335–345, 10.1530/REP-13-0175.
125. Shah, S.J., Yu, K.H., Sangar, V., Parry, S.I., Blair, I.A., Identification and quantification of preterm birth biomarkers in human cervicovaginal fluid by liquid chromatography/tandem mass spectrometry. J. Proteome Res. 8 (2009), 2407–2417, 10.1021/pr8010342.
126. Van Raemdonck, G.A.A., Tjalma, W.A.A., Coen, E.P., Depuydt, C.E., Van Ostade, X.W.M., Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid. PLoS One, 9, 2014, e106488, 10.1371/journal.pone.0106488.
127. Van Raemdonck, G., Zegels, G., Coen, E., Vuylsteke, B., Jennes, W., Van Ostade, X., Increased Serpin A5 levels in the cervicovaginal fluid of HIV-1 exposed seronegatives suggest that a subtle balance between serine proteases and their inhibitors may determine susceptibility to HIV-1 infection. Virology 458–459 (2014), 11–21, 10.1016/j.virol.2014.04.015.
128. Christensen, E.I., Gburek, J., Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology. Pediatric Nephrology (Berlin, Germany) 19 (2004), 714–721, 10.1007/s00467-004-1494-0.
129. Haraldsson, B., Sörensson, J., Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol. Sci. 19 (2004), 7–10.
130. McDougal, W.S., Wein, A.J., Kavoussi, L.R., Novick, A.C., Partin, A.W., Peters, C.A., et al. Campbell-Walsh Urology 10th Edition Review. 2011.
131. Clarke, S.H., Investigation into methods of collection of urine for culture from men and women. Br. Med. J. 2 (1960), 1491–1493 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2097631&tool=pmcentrez&rendertype=abstract (accessed February 15, 2016).
132. Brunzel, N.A., Fundamentals of Urine and Body Fluid Analysis. 3rd ed, 2013, Elsevier/Saunders, St. Louis, Mo.
133. Bradbury, S.M., Collection of urine specimens in general practice: to clean or not to clean?. J. R. Coll. Gen. Pract. 38 (1988), 363–365.
134. Cui, S., Verroust, P.J., Moestrup, S.K., Christensen, E.I., Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am. J. Physiol. 271 (1996), F900–F907 http://www.ncbi.nlm.nih.gov/pubmed/8898021 (accessed January 24, 2016).
135. Pisitkun, T., Shen, R.-F., Knepper, M.A., Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. 101 (2004), 13368–13373, 10.1073/pnas.0403453101.
136. Castagna, A., Cecconi, D., Sennels, L., Rappsilber, J., Guerrier, L., Fortis, F., et al. Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res. 4 (2006), 1917–1930, 10.1021/pr050153r.
137. Pieper, R., Gatlin, C.L., McGrath, A.M., Makusky, A.J., Mondal, M., Seonarain, M., et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4 (2004), 1159–1174, 10.1002/pmic.200300661.
138. Wang, L., Li, F., Sun, W., Wu, S., Wang, X., Zhang, L., et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol. Cell. Proteomics 5 (2006), 560–562, 10.1074/mcp.D500013-MCP200.
139. Sun, W., Li, F., Wu, S., Wang, X., Zheng, D., Wang, J., et al. Human urine proteome analysis by three separation approaches. Proteomics 5 (2005), 4994–5001, 10.1002/pmic.200401334.
140. Locatelli, F., Canaud, B., Eckardt, K.U., Stenvinkel, P., Wanner, C., Zoccali, C., The importance of diabetic nephropathy in current nephrological practice. J. Control. Release 18 (2003), 1716–1725, 10.1093/ndt/gfg288.
141. Otu, H.H., Can, H., Spentzos, D., Nelson, R.G., Hanson, R.L., Looker, H.C., et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 30 (2007), 638–643, 10.2337/dc06-1656.
142. Coon, J.J., Zürbig, P., Dakna, M., Dominiczak, A.F., Decramer, S., Fliser, D., et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl., 2, 2008, 964, 10.1002/prca.200800024.
143. Rehman, I., Azzouzi, A.R., Catto, J.W.F., Allen, S., Cross, S.S., Feeley, K., et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 64 (2004), 1238–1243, 10.1016/j.urology.2004.06.063.
144. Bakun, M., Niemczyk, M., Domanski, D., Jazwiec, R., Perzanowska, A., Niemczyk, S., et al. Urine proteome of autosomal dominant polycystic kidney disease patients. Clinical Proteomics, 9, 2012, 13, 10.1186/1559-0275-9-13.
145. Quintana, L.F., Campistol, J.M., Alcolea, M.P., Bañon-Maneus, E., Sol-González, A., Cutillas, P.R., Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol. Cell. Proteomics 8 (2009), 1658–1673, 10.1074/mcp.M900059-MCP200.
146. Johnston, O., Cassidy, H., O'Connell, S., O'Riordan, A., Gallagher, W., Maguire, P.B., et al. Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. Proteomics Clin. Appl. 5 (2011), 422–431, 10.1002/prca.201000160.
147. Lacroix, C., Caubet, C., Gonzalez-de-Peredo, A., Breuil, B., Bouyssié, D., Stella, A., et al. Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy. Mol. Cell. Proteomics 13 (2014), 3421–3434, 10.1074/mcp.M114.040121.
148. Oates, J.C., Varghese, S., Bland, A.M., Taylor, T.P., Self, S.E., Stanislaus, R., et al. Prediction of urinary protein markers in lupus nephritis. Kidney Int. 68 (2005), 2588–2592, 10.1111/j.1523-1755.2005.00730.x.
149. Cadieux, P.A., Beiko, D.T., Watterson, J.D., Burton, J.P., Howard, J.C., Knudsen, B.E., et al. Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J. Clin. Lab. Anal. 18 (2004), 170–175, 10.1002/jcla.20018.
150. Saito, M., Kimoto, M., Araki, T., Shimada, Y., Fujii, R., Oofusa, K., et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur. Urol. 48 (2005), 865–871, 10.1016/j.eururo.2005.04.028.
151. Ostergaard, M., Rasmussen, H.H., Nielsen, H.V., Vorum, H., Orntoft, T.F., Wolf, H., et al. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res. 57 (1997), 4111–4117 http://www.ncbi.nlm.nih.gov/pubmed/9307301 (accessed January 27, 2016).
152. Kageyama, S., Isono, T., Iwaki, H., Wakabayashi, Y., Okada, Y., Kontani, K., et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin. Chem. 50 (2004), 857–866, 10.1373/clinchem.2003.027425.
153. Chen, C.-L., Lin, T.-S., Tsai, C.-H., Wu, C.-C., Chung, T., Chien, K.-Y., et al. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. J. Proteomics 85 (2013), 28–43, 10.1016/j.jprot.2013.04.024.
154. Chen, Y.-T., Chen, C.-L., Chen, H.-W., Chung, T., Wu, C.-C., Chen, C.-D., et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J. Proteome Res. 9 (2010), 5803–5815, 10.1021/pr100576x.
155. Wu, J., Chen, Y., Gu, W., Urinary proteomics as a novel tool for biomarker discovery in kidney diseases. J. Zhejiang Univ. Sci. B 11 (2010), 227–237, 10.1631/jzus.B0900327.
156. Yang, N., Feng, S., Shedden, K., Xie, X., Liu, Y., Rosser, C.J., et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin. Cancer Res. 17 (2011), 3349–3359, 10.1158/1078-0432.CCR-10-3121.
157. Chen, Y.-T., Chen, H.-W., Domanski, D., Smith, D.S., Liang, K.-H., Wu, C.-C., et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J. Proteomics 75 (2012), 3529–3545, 10.1016/j.jprot.2011.12.031.
158. G. Alves, D.A. Pereira, V. Sandim, A.A. Ornellas, N. Escher, C. Melle, et al., Urine screening by Seldi-Tof, followed by biomarker identification, in a Brazilian cohort of patients with renal cell carcinoma (RCC)., Int. Braz J Urol. 39 228–39.
159. Wu, D.-L., Zhang, W.-H., Wang, W.-J., Jing, S.-B., Xu, Y.-M., Proteomic evaluation of urine from renal cell carcinoma using SELDI-TOF-MS and tree analysis pattern. Technol. Cancer Res. Treat. 7 (2008), 155–160.
160. Mueller, J., Von Eggeling, F., Driesch, D., Schubert, J., Melle, C., Junker, K., ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur. Urol. 47 (2005), 885–894, 10.1016/j.eururo.2005.02.016.
161. Vlahou, A., Schellhammer, P.F., Mendrinos, S., Patel, K., Kondylis, F.I., Gong, L., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158 (2001), 1491–1502, 10.1016/S0002-9440(10)64100-4.
162. McAteer, M.A., Akhtar, A.M., von Zur Muhlen, C., Choudhury, R.P., An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis 209 (2010), 18–27, 10.1016/j.atherosclerosis.2009.10.009.
163. von Zur Muhlen, C., Schiffer, E., Zuerbig, P., Kellmann, M., Brasse, M., Meert, N., et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J. Proteome Res. 8 (2009), 335–345, 10.1021/pr800615t.
164. Gozal, D., Jortani, S., Snow, A.B., Kheirandish-Gozal, L., Bhattacharjee, R., Kim, J., et al. Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in pediatric obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 180 (2009), 1253–1261, 10.1164/rccm.200905-0765OC.
165. Ye, B., Skates, S., Mok, S.C., Horick, N.K., Rosenberg, H.F., Vitonis, A., et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 12 (2006), 432–441, 10.1158/1078-0432.CCR-05-0461.
166. Beretov, J., Wasinger, V.C., Millar, E.K.A., Schwartz, P., Graham, P.H., Li, Y., Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach. PLoS One, 10, 2015, e0141876, 10.1371/journal.pone.0141876.
167. Su, L., Cao, L., Zhou, R., Jiang, Z., Xiao, K., Kong, W., et al. Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS. PLoS One, 8, 2013, e54237, 10.1371/journal.pone.0054237.
168. Su, L., Zhou, R., Liu, C., Wen, B., Xiao, K., Kong, W., et al. Urinary proteomics analysis for sepsis biomarkers with iTRAQ labeling and two-dimensional liquid chromatography-tandem mass spectrometry. J. Trauma Acute Care Surg. 74 (2013), 940–945, 10.1097/TA.0b013e31828272c5.
169. Vestergaard, P., Leverett, R., Constancy of urinary creatinine excretion. J. Lab. Clin. Med. 51 (1958), 211–218.
170. Theodorescu, D., Fliser, D., Wittke, S., Mischak, H., Krebs, R., Walden, M., et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 26 (2005), 2797–2808, 10.1002/elps.200400208.
171. Shi, M., Caudle, W.M., Zhang, J., Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis. 35 (2009), 157–164, 10.1016/j.nbd.2008.09.004.
172. Sigdel, T.K., Nicora, C.D., Hsieh, S.-C., Dai, H., Qian, W.-J., Camp, D.G., et al. Optimization for peptide sample preparation for urine peptidomics. Clinical Proteomics, 11, 2014, 7, 10.1186/1559-0275-11-7.
173. Olszowy, P., Buszewski, B., Urine sample preparation for proteomic analysis. J. Sep. Sci. 37 (2014), 2920–2928, 10.1002/jssc.201400331.
174. Thomas, S., Hao, L., Ricke, W.A., Li, L., Biomarker discovery in mass spectrometry-based urinary proteomics. Proteomics Clin. Appl. 10:4 (2016), 358–370, 10.1002/prca.201500102.
175. Kalantari, S., Jafari, A., Moradpoor, R., Ghasemi, E., Khalkhal, E., Human urine proteomics: analytical techniques and clinical applications in renal diseases. International Journal of Proteomics, 2015, 2015, 782798, 10.1155/2015/782798.
176. Kim, M.J., Frankel, A.H., Tam, F.W.K., Urine proteomics and biomarkers in renal disease. Nephron Exp. Nephrol. 119 (2011), e1–e7, 10.1159/000324223.
177. Ganz, T., The role of antimicrobial peptides in innate immunity. Integr. Comp. Biol. 43 (2003), 300–304, 10.1093/icb/43.2.300.
178. Schommer, N.N., Gallo, R.L., Structure and function of the human skin microbiome. Trends Microbiol. 21 (2013), 660–668, 10.1016/j.tim.2013.10.001.
179. Kalló, G., Chatterjee, A., Tóth, M., Rajnavölgyi, É., Csutak, A., Tőzsér, J., et al. Relative quantification of human β-defensins by a proteomics approach based on selected reaction monitoring. Rapid Commun. Mass Spectrom. 29 (2015), 1623–1631, 10.1002/rcm.7259.
180. Zasloff, M., Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J. Am. Soc. Nephrol. 18 (2007), 2810–2816, 10.1681/ASN.2007050611.
181. Marquis, G., Garzon, S., Strykowski, H., Auger, P., Cell walls of normal and lysozyme-damaged blastoconidia of Candida albicans: localization of surface factor 4 antigen and vicinal-glycol staining. Infect. Immun. 59 (1991), 1312–1318.
182. Lee-Huang, S., Huang, P.L., Sun, Y., Kung, H.F., Blithe, D.L., Chen, H.C., Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 2678–2681.
183. Flo, T.H., Smith, K.D., Sato, S., Rodriguez, D.J., Holmes, M.A., Strong, R.K., et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432 (2004), 917–921, 10.1038/nature03104.
184. Yang, J., Goetz, D., Li, J.Y., Wang, W., Mori, K., Setlik, D., et al. An iron delivery pathway mediated by a lipocalin. Mol. Cell 10 (2002), 1045–1056.
185. McKown, R.L., Wang, N., Raab, R.W., Karnati, R., Zhang, Y., Williams, P.B., et al. Lacritin and other new proteins of the lacrimal functional unit. Exp. Eye Res. 88 (2009), 848–858, 10.1016/j.exer.2008.09.002.
186. Wang, J., Wang, N., Xie, J., Walton, S.C., McKown, R.L., Raab, R.W., et al. Restricted epithelial proliferation by lacritin via PKCalpha-dependent NFAT and mTOR pathways. J. Cell Biol. 174 (2006), 689–700, 10.1083/jcb.200605140.
187. Wang, W., Despanie, J., Shi, P., Edman-Woolcott, M.C., Lin, Y.-A., Cui, H., et al. Lacritin-mediated regeneration of the corneal epithelia by protein polymer nanoparticles. Journal of Materials Chemistry. B, Materials for Biology and Medicine 2 (2014), 8131–8141, 10.1039/C4TB00979G.
188. McKown, R.L., Coleman Frazier, E.V., Zadrozny, K.K., Deleault, A.M., Raab, R.W., Ryan, D.S., et al. A cleavage-potentiated fragment of tear lacritin is bactericidal. J. Biol. Chem. 289 (2014), 22172–22182, 10.1074/jbc.M114.570143.
189. Kowluru, R.A., Mishra, M., Contribution of epigenetics in diabetic retinopathy. Sci. China Life Sci. 58 (2015), 556–563, 10.1007/s11427-015-4853-0.
190. Cheung, N., Mitchell, P., Wong, T.Y., Diabetic retinopathy. Lancet 376 (2010), 124–136, 10.1016/S0140-6736(09)62124-3.
191. Lutty, G.A., Effects of diabetes on the eye. Invest. Ophthalmol. Vis. Sci. 54 (2013), 81–87, 10.1167/iovs.13-12979.
192. Dastur, Y.K., The rationale of argon green laser photocoagulation for diabetic maculopathy. J. Postgrad. Med. 40 (1994), 13–17.
193. Gutiérrez-vázquez, C., Villarroya-beltri, C., Mittelbrunn, M., Transfer of extracellular vesicles during immune cell-cell interactions. Immunol. Rev. 251 (2013), 125–142, 10.1111/imr.12013.Transfer.
194. Yoon, Y.J., Kim, O.Y., Gho, Y.S., Extracellular vesicles as emerging intercellular communicasomes. BMB Rep. 47 (2014), 531–539, 10.5483/BMBRep.2014.47.10.164.
195. Turturici, G., Tinnirello, R., Sconzo, G., Geraci, F., Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am. J. Physiol. Cell Physiol. 306 (2014), C621–C633, 10.1152/ajpcell.00228.2013.
196. Gould, S.J., Raposo, G., As we wait: coping with an imperfect nomenclature for extracellular vesicles. Journal of Extracellular Vesicles 2 (2013), 3–5, 10.3402/jev.v2i0.20389.
197. Caby, M.-P., Lankar, D., Claude, V.-S., Raposo, G., Bonnerot, C., Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17 (2005), 879–887, 10.1093/intimm/dxh267.
198. Nilsson, J., Skog, J., Nordstrand, A., Baranov, V., Mincheva-Nilsson, L., Breakefield, X.O., et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100 (2009), 1603–1607, 10.1038/sj.bjc.6605058.
199. Keller, S., Ridinger, J., Rupp, A.-K., Janssen, J.W.G., Altevogt, P., Body fluid derived exosomes as a novel template for clinical diagnostics. J. Transl. Med., 9, 2011, 86, 10.1186/1479-5876-9-86.
200. Ogawa, Y., Miura, Y., Harazono, A., Kanai-Azuma, M., Akimoto, Y., Kawakami, H., et al. Proteomic analysis of two types of exosomes in human whole saliva. Biol. Pharm. Bull. 34 (2011), 13–23, 10.1248/bpb.34.13.
201. Qazi, K.R., Torregrosa Paredes, P., Dahlberg, B., Grunewald, J., Eklund, A., Gabrielsson, S., Proinflammatory exosomes in bronchoalveolar lavage fluid of patients with sarcoidosis. Thorax 65 (2010), 1016–1024, 10.1136/thx.2009.132027.
202. Admyre, C., Johansson, S.M., Qazi, K.R., Filén, J.-J., Lahesmaa, R., Norman, M., et al. Exosomes with immune modulatory features are present in human breast milk. J. Immunol. 179 (2007), 1969–1978, 10.4049/jimmunol.179.3.1969.
203. Little, K.M., Smalley, D.M., Harthun, N.L., Ley, K., The plasma microparticle proteome. Semin. Thromb. Hemost. 36 (2010), 845–856, 10.1055/s-0030-1267038.
204. Harel, M., Oren-Giladi, P., Kaidar-Person, O., Shaked, Y., Geiger, T., Proteomics of microparticles with SILAC quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification. Molecular & Cellular Proteomics: MCP. 14 (2015), 1127–1136, 10.1074/mcp.M114.043364.
205. Barteneva, N.S., Fasler-Kan, E., Bernimoulin, M., Stern, J.N.H., Ponomarev, E.D., Duckett, L., et al. Circulating microparticles: square the circle. BMC Cell Biol., 14, 2013, 23, 10.1186/1471-2121-14-23.
206. Yáñez-Mó, M., Siljander, P.R.-M., Andreu, Z., Zavec, A.B., Borràs, F.E., Buzas, E.I., et al. Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 4, 2015, 27066, 10.3402/jev.v4.27066.
207. De Toro, J., Herschlik, L., Waldner, C., Mongini, C., Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front. Immunol., 6, 2015, 203, 10.3389/fimmu.2015.00203.
208. Duijvesz, D., Burnum-Johnson, K.E., Gritsenko, M.A., Hoogland, A.M., Vredenbregt-van Den Berg, M.S., Willemsen, R., et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One, 8, 2013, 10.1371/journal.pone.0082589.
209. Rood, I.M., Deegens, J.K.J., Merchant, M.L., Tamboer, W.P.M., Wilkey, D.W., Wetzels, J.F.M., et al. Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. Kidney Int. 78 (2010), 810–816, 10.1038/ki.2010.262.
210. Moon, P.G., Lee, J.E., You, S., Kim, T.K., Cho, J.H., Kim, I.S., et al. Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 11 (2011), 2459–2475, 10.1002/pmic.201000443.
211. Smalley, D.M., Sheman, N.E., Nelson, K., Theodorescu, D., Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J. Proteome Res. 7 (2008), 2088–2096, 10.1021/pr700775x.
212. Chen, C.L., Lai, Y.F., Tang, P., Chien, K.Y., Yu, J.S., Tsai, C.H., et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J. Proteome Res. 11 (2012), 5611–5629, 10.1021/pr3008732.
213. Ramacciotti, E., Hawley, A.E., Wrobleski, S.K., Myers, D.D., Strahler, J.R., Andrews, P.C., et al. Proteomics profiling of plasma microparticles following deep-vein thrombosis. Expert Rev. Proteomics 125 (2010), 327–330, 10.1016/j.thromres.2010.01.019.
214. Ramacciotti, E., Hawley, A.E., Wrobleski, S.K., Myers, D.D., Strahler, J.R., Andrews, P.C., et al. Proteomics of microparticles after deep venous thrombosis. Thromb. Res., 125, 2010, 10.1016/j.thromres.2010.01.019.
215. Graner, M.W., Alzate, O., Dechkovskaia, A.M., Keene, J.D., Sampson, J.H., Mitchell, D.A., et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 23 (2008), 1541–1557, 10.1096/fj.08-122184.